Life science organizations that will lead the next decade ar those that deploy systems that are scientifically credible, clinically defensible, regulatorily traceable, and operationally sustained.
Partha Anbil
Advertisement
Partha Anbil is at the intersection of the Life Sciences industry and Management Consulting. He is currently SVP, Life Sciences, at Coforge Limited, a $1.7B multinational digital solutions and technology consulting services company. He held senior leadership roles at WNS, IBM, Booz & Company, Symphony, IQVIA, KPMG Consulting, and PWC. Mr. Anbil has consulted with and counseled Health and Life Sciences clients on structuring solutions to address strategic, operational, and organizational challenges. He was a member of the IBM Industry Academy, a very selective group of professionals inducted into the academy by invitation only, the highest honor at IBM. He is a healthcare expert member of the World Economic Forum (WEF). He is also a Life Sciences industry advisor at MIT, his alma mater.
Articles by Partha Anbil
Recent breakthroughs in artificial intelligence allow specialized language models to automatically extract critical information from thousands of complex drug labels in minutes instead of days.
Reliable, domain-specific AI models grounded in validated clinical evidence are emerging as essential to safely scaling generative AI across healthcare applications.
Large language models and natural language processing are reshaping drug safety surveillance by enabling automated adverse event detection, large-scale analysis of regulatory labeling data, and faster, citation-grounded safety assessments while maintaining human oversight and regulatory compliance.
As the AI-first era matures, life sciences leaders must pivot from narrow, task-specific models toward integrated, interpretable frameworks that transform biological complexity into a sustainable competitive advantage.
Advertisement
Latest Updated Articles
Advertisement
Advertisement